 Verapamil
"Verapamil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A calcium channel blocker that is a class IV anti-arrhythmia agent.
| Descriptor ID |
D014700
|
| MeSH Number(s) |
D02.092.471.683.953
|
| Concept/Terms |
Lekoptin- Lekoptin
- Sandoz Brand of Verapamil
- Verapamil Sandoz Brand
|
Below are MeSH descriptors whose meaning is more general than "Verapamil".
Below are MeSH descriptors whose meaning is more specific than "Verapamil".
This graph shows the total number of publications written about "Verapamil" by people in this website by year, and whether "Verapamil" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 2 | 0 | 2 | | 1984 | 0 | 1 | 1 | | 1985 | 1 | 2 | 3 | | 1990 | 0 | 2 | 2 | | 1991 | 1 | 1 | 2 | | 1992 | 0 | 2 | 2 | | 1993 | 2 | 4 | 6 | | 1994 | 1 | 2 | 3 | | 1995 | 0 | 1 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 2 | 2 | 4 | | 1998 | 5 | 1 | 6 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 3 | 2 | 5 | | 2002 | 3 | 0 | 3 | | 2003 | 5 | 2 | 7 | | 2004 | 1 | 2 | 3 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 2 | 3 | | 2007 | 4 | 1 | 5 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 1 | 2 | | 2011 | 1 | 2 | 3 | | 2012 | 1 | 1 | 2 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Verapamil" by people in Profiles.
-
Magvanjav O, Gong Y, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshees AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
-
Narayanan J, Frech R, Walters S, Patel V, Frigerio R, Maraganore DM. Low dose verapamil as an adjunct therapy for medically refractory epilepsy - An open label pilot study. Epilepsy Res. 2016 10; 126:197-200.
-
Vandell AG, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG, Beitelshees AL, Turner ST, Chapman AB, Cooper-DeHoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 polymorphisms: ß-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct; 60(4):957-64.
-
Levine LA, Costabile RA. Is intralesional verapamil effective therapy for Peyronie's disease? J Urol. 2012 Sep; 188(3):704-6.
-
Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. J Sex Med. 2012 Jan; 9(1):288-95.
-
Brueggemann LI, Kakad PP, Love RB, Solway J, Dowell ML, Cribbs LL, Byron KL. Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy. . 2012 Jan 01; 302(1):L120-32.
-
Levine LA. Current approach to the man with acute phase Peyronie's disease--case presentation and discussion. J Sex Med. 2011 Jun; 8(6):1556-8; quiz 1559.
-
Bergson P, Lipkind G, Lee SP, Duban ME, Hanck DA. Verapamil block of T-type calcium channels. Mol Pharmacol. 2011 Mar; 79(3):411-9.
-
Shah DP, Baez-Escudero JL, Weisberg IL, Beshai JF, Burke MC. Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8). Pacing Clin Electrophysiol. 2012 Mar; 35(3):e62-4.
-
Vardi Y, Levine LA, Chen J, Hatzimouratidis K, Sohn M. Is there a place for conservative treatment in Peyronie's disease? J Sex Med. 2009 Apr; 6(4):903-909.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|